Diffusion Pharmaceuticals Stock Forecast, Price & News

-0.02 (-2.78 %)
(As of 09/16/2021 02:40 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,390 shs
Average Volume3.85 million shs
Market Capitalization$54.49 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DFFN News and Ratings via Email

Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Diffusion Pharmaceuticals logo

About Diffusion Pharmaceuticals

Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.00 out of 5 stars

Medical Sector

1210th out of 1,352 stocks

Pharmaceutical Preparations Industry

590th out of 665 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Diffusion Pharmaceuticals (NASDAQ:DFFN) Frequently Asked Questions

Is Diffusion Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Diffusion Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DFFN, but not buy additional shares or sell existing shares.
View analyst ratings for Diffusion Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Diffusion Pharmaceuticals?

Wall Street analysts have given Diffusion Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Diffusion Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals saw a decrease in short interest in August. As of August 13th, there was short interest totaling 1,350,000 shares, a decrease of 18.7% from the July 29th total of 1,660,000 shares. Based on an average trading volume of 1,460,000 shares, the days-to-cover ratio is presently 0.9 days. Currently, 1.3% of the shares of the stock are short sold.
View Diffusion Pharmaceuticals' Short Interest

When is Diffusion Pharmaceuticals' next earnings date?

Diffusion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Diffusion Pharmaceuticals

How were Diffusion Pharmaceuticals' earnings last quarter?

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) issued its earnings results on Wednesday, August, 11th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01.
View Diffusion Pharmaceuticals' earnings history

How has Diffusion Pharmaceuticals' stock price been impacted by Coronavirus?

Diffusion Pharmaceuticals' stock was trading at $0.3434 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, DFFN stock has increased by 55.6% and is now trading at $0.5345.
View which stocks have been most impacted by COVID-19

When did Diffusion Pharmaceuticals' stock split? How did Diffusion Pharmaceuticals' stock split work?

Shares of Diffusion Pharmaceuticals reverse split on Friday, December 14th 2018. The 1-15 reverse split was announced on Thursday, December 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 13th 2018. An investor that had 100 shares of Diffusion Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

Who are Diffusion Pharmaceuticals' key executives?

Diffusion Pharmaceuticals' management team includes the following people:
  • Robert J. Cobuzzi, President, Chief Executive Officer & Director
  • William Hornung, Chief Financial Officer
  • Christopher D. Galloway, Chief Medical Officer
  • Harry N. Cook, Vice President-Clinical Operations
  • William R. Elder, Secretary & General Counsel

Who are some of Diffusion Pharmaceuticals' key competitors?

What other stocks do shareholders of Diffusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE) and Enerplus (ERF).

What is Diffusion Pharmaceuticals' stock symbol?

Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."

Who are Diffusion Pharmaceuticals' major shareholders?

Diffusion Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.52%), Renaissance Technologies LLC (1.35%), Geode Capital Management LLC (0.79%), State Street Corp (0.45%) and Citadel Advisors LLC (0.15%). Company insiders that own Diffusion Pharmaceuticals stock include Jane H Hollingsworth, Robert Joseph Jr Cobuzzi and William Robert Elder.
View institutional ownership trends for Diffusion Pharmaceuticals

Which institutional investors are selling Diffusion Pharmaceuticals stock?

DFFN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Diffusion Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Diffusion Pharmaceuticals stock?

DFFN stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., State Street Corp, Citadel Advisors LLC, and Geode Capital Management LLC. Company insiders that have bought Diffusion Pharmaceuticals stock in the last two years include Jane H Hollingsworth, Robert Joseph Jr Cobuzzi, and William Robert Elder.
View insider buying and selling activity for Diffusion Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Diffusion Pharmaceuticals?

Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Diffusion Pharmaceuticals' stock price today?

One share of DFFN stock can currently be purchased for approximately $0.53.

How much money does Diffusion Pharmaceuticals make?

Diffusion Pharmaceuticals has a market capitalization of $54.47 million. The company earns $-14,190,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

How many employees does Diffusion Pharmaceuticals have?

Diffusion Pharmaceuticals employs 14 workers across the globe.

What is Diffusion Pharmaceuticals' official website?

The official website for Diffusion Pharmaceuticals is

Where are Diffusion Pharmaceuticals' headquarters?

Diffusion Pharmaceuticals is headquartered at 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902.

How can I contact Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at (434) 220-0718 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.